13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001534261
Total reported value
$2.0B
$2.0B
36 檔
35.6%
As reported in its official Q1 2024 Form 13F filing, Casdin Capital, LLC's tracked investment portfolio stood at $2.0B with 36 total positions.
During Q1 2024, Casdin Capital, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including RVMD, LAB, BLFS) accounted for 35.6% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 13.46% | +5.18% | -1.70% | |
| 2 | LAB | Standard Biotools Inc | Stock-Other | 12.47% | -2.52% | +5058.97% | |
| 3 | BLFS | Biolife Solutions Inc | Stock-Other | 12.01% | -2.03% | — | |
| 4 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 10.29% | +0.42% | NEW | |
| 5 | RLAY | Relay Therapeutics Inc | Stock-Other | 4.58% | +4.16% | +0.48% | |
| 6 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 3.98% | -0.75% | +83.59% | |
| 7 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 3.96% | — | +77.32% | |
| 8 | NTLA | Intellia Therapeutics Inc | Stock-Other | 3.94% | -0.04% | +32.76% | |
| 9 | GPCR | Structure Therapeutics Inc | Stock-Other | 3.56% | -1.13% | — | |
| 10 | EXK | Exact Sciences CORP | Stock-Materials | 3.34% | — | +54.76% | |
| 11 | ✓ | Verve Therapeutics Inc | Stock-Other | 3.02% | — | +1.66% | |
| 12 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 2.62% | -0.01% | +5.51% | |
| 13 | ILMN | Illumina Inc | Stock-Healthcare | 2.53% | -0.29% | -26.63% | |
| 14 | 2655787D | Blueprint Medicines CORP | Stock-Other | 2.30% | — | — | |
| 15 | WGS | Genedx Holdings CORP | Stock-Other | 2.13% | -1.88% | +1.32% | |
| 16 | NGNE | Neurogene Inc | Stock-Other | 1.99% | +0.26% | — | |
| 17 | DNLI | Denali Therapeutics Inc | Stock-Other | 1.98% | -0.05% | — | |
| 18 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 1.89% | — | -22.62% | |
| 19 | BEAM | Beam Therapeutics Inc | Stock-Other | 1.66% | -0.12% | +27.84% | |
| 20 | VCYT | Veracyte Inc | Stock-Other | 1.41% | +0.14% | — | |
| 21 | PLRX | Pliant Therapeutics Inc | Stock-Other | 1.11% | — | -36.59% | |
| 22 | IPSC | Century Therapeutics Inc | Stock-Other | 1.00% | -0.06% | — | |
| 23 | TSVT* | 2seventy Bio Inc | Stock-Other | 0.80% | — | +69.12% | |
| 24 | ABCL | Abcellera Biologics Inc | Stock-Other | 0.79% | — | — | |
| 25 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.70% | — | — | |
| 26 | CDXS | Codexis Inc | Stock-Other | 0.52% | — | — | |
| 27 | ABSI | Absci CORP | Stock-Other | 0.41% | +0.34% | — | |
| 28 | PACB | Pacific Biosciences Of Calif | Stock-Other | 0.29% | -0.01% | — | |
| 29 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.28% | — | — | |
| 30 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.27% | — | — | |
| 31 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.27% | — | — | |
| 32 | PRME | Prime Medicine Inc | Stock-Other | 0.19% | -0.25% | — | |
| 33 | DNA4EUR | Ginkgo Bioworks Holdings Inc | Stock-Other | 0.13% | — | — | |
| 34 | EXAIEUR | Exscientia PLC | Stock-Other | 0.09% | — | — | |
| 35 | ✓ | Singular Genomics Systems In | Stock-Other | 0.05% | — | — | |
| 36 | KRON1USD | Kronos Bio Inc | Stock-Other | 0.01% | — | — |
According to official SEC Form 13F filings, Casdin Capital, LLC reported a total U.S. public equity portfolio value of $2.0B across 36 disclosed positions in Q1 2024.
During Q1 2024, Casdin Capital, LLC's top holdings by market value included RVMD (13.5%)、LAB (12.5%)、BLFS (12.0%). The largest single position, RVMD, represented 13.5% of total portfolio value.
In Q1 2024, Casdin Capital, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.